A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
NCT05235542 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 130
Last updated 2022-08-11
Summary
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) and AK117#AntiCD47 Antibody# combined with or without chemotherapy in advanced malignant tumors
Conditions
- Advanced Malignant Tumors
Interventions
- DRUG
-
AK104
IV infusion,Specified dose on specified days
- DRUG
-
AK117
IV infusion,Specified dose on specified days
- DRUG
-
Capecitabine tablets
Oral,Specified dose on specified days
- DRUG
-
IV infusion,Specified dose on specified days
- DRUG
-
IV infusion,Specified dose on specified days
- DRUG
-
IV infusion,Specified dose on specified days
- DRUG
-
IV infusion,Specified dose on specified days
- DRUG
-
IV infusion,Specified dose on specified days
- DRUG
-
IV infusion,Specified dose on specified days
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Liwei Wang, MD · RenJi Hospital
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-07-12
- Primary Completion
- 2023-03-31
- Completion
- 2024-03-31
Countries
- China
Study Locations
More Related Trials
-
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
NCT04172506 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
NCT05116007 ·Status: COMPLETED ·Phase: PHASE1
-
AK129 Combination Therapy for Advanced Solid Tumors
NCT06943820 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
NCT06166472 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
NCT05142423 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of AK129 in Patients With Advanced Malignant Tumors
NCT05645276 ·Status: RECRUITING ·Phase: PHASE1
-
Study of AK112 in the Treatment of Advanced Gynecological Tumors
NCT04870177 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor
NCT04291248 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
NCT05689853 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma
NCT06586294 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB
NCT05295212 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263 ·Status: RECRUITING ·Phase: PHASE3
-
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
NCT05420220 ·Status: RECRUITING ·Phase: PHASE2
-
Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors
NCT04588324 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma
NCT03866967 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
NCT06238401 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of AK131 in Patients With Advanced Solid Tumors
NCT06166888 ·Status: RECRUITING ·Phase: PHASE1
-
Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
NCT06532591 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
NCT06692491 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
NCT06211114 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
NCT07331155 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
NCT07170787 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors
NCT05309512 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
NCT04004234 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients
NCT05097781 ·Status: UNKNOWN ·Phase: PHASE2